Fingolimod (Gilenya): MS Clinical Trials
8 active trials · 3 recruiting
8 active multiple sclerosis clinical trials involve Fingolimod (Gilenya), 3 currently recruiting. The list is matched on the interventions registered at ClinicalTrials.gov, so it includes head-to-head comparisons and studies where this therapy is the comparator as well as the treatment under test.
Trial results are not treatment advice: whether a therapy is right for you depends on your type of MS, disease activity and history, which is a conversation for your neurologist.
Active Fingolimod (Gilenya) MS trials
RecruitingPhase 4
Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis
Sponsor: Novartis Pharmaceuticals
Fingolimod
30 participantsDetails ›
RecruitingPhase 3
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
Sponsor: Celgene
Ozanimod · Fingolimod
9 states194 participantsDetails ›
Recruiting
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
Sponsor: Biogen
Diroximel Fumarate · Alemtuzumab
1 state1178 participantsDetails ›
By invitation only
Relationship Between Oral DMT Burden and Adherence in MS
Sponsor: Monash University
Cladribine · Dimethyl fumarate
323 participantsDetails ›
Closed to new patientsPhase 3
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
Sponsor: Novartis Pharmaceuticals
Fingolimod · Ofatumumab
6 states129 participantsDetails ›
Closed to new patientsPhase 3
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)
Sponsor: Hoffmann-La Roche
Ocrelizumab · Ocrelizumab Placebo
11 states188 participantsDetails ›
Closed to new patientsPhase 3
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
Sponsor: Novartis Pharmaceuticals
Interferon beta-1a · Fingolimod
8 states240 participantsDetails ›
Closed to new patientsNA
Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial
Sponsor: Johns Hopkins University
Natalizumab/natalizumab-sztn, Alemtuz… · Glatiramer acetate, Interferons (intr…
28 states900 participantsDetails ›
MS trials by therapy
Exercise and rehabilitation (81)Ocrelizumab (Ocrevus) (34)Ofatumumab (Kesimpta) (18)Diet and nutrition (12)Teriflunomide (Aubagio) (9)Ublituximab (Briumvi) (7)Cladribine (Mavenclad) (7)Rituximab (6)Ozanimod (Zeposia) (6)Dimethyl fumarate (Tecfidera) (6)Interferon beta (5)Fenebrutinib (5)Stem cell therapy (aHSCT and MSC) (5)Natalizumab (Tysabri) (4)Siponimod (Mayzent) (4)Remibrutinib (4)CAR-T cell therapy (4)Alemtuzumab (Lemtrada) (3)Glatiramer acetate (Copaxone) (3)Frexalimab (3)Metformin (3)Cannabis and cannabinoids (3)
The app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.